Faeth Therapeutics, Inc. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Faeth Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2021-03-31 was $95.83M, a 101.55% increase year-over-year.
- Faeth Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2020-03-31 was $47.55M.
- Faeth Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2021 was $95.83M, a 101.55% increase from fiscal 2020.
- Faeth Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2020 was $47.55M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2021-12-31 | $95.83M 10-K · filed 2023-03-29 | |
| 2021-03-31 | $95.83M 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $47.55M 10-K · filed 2022-03-15 | |
| 2020-03-31 | $47.55M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |